FDA Accepts Biologic License Application for AVT03 by Alvotech and Dr. Reddy's

🔬 The U.S. FDA has accepted the Biologic License Application for AVT03, a proposed biosimilar to Prolia® and Xgeva®, developed by Alvotech and

. This milestone advances the regulatory pathway for introducing a new biosimilar to the market.